Hong Kong WinHealth Pharma Group to acquire the China business of Kyowa Kirin for $100m.

Hong Kong WinHealth Pharma Group, a biotechnology company, providing novel therapies to patients with rare diseases, agreed to acquire the China business of Kyowa Kirin, a global specialty pharmaceutical company that applies biotechnologies to discover and deliver novel medicines, for $100m. "Guided by our 'Story for Vision 2030', we have developed a strategy to continue delivering life-changing value and shape the future of Kyowa Kirin. We have defined our focus disease areas and identified opportunities to maximize the value of our products through in-house efforts and strategic partnerships. Recognizing the increasing challenges in the APAC region, we have made the difficult decision to restructure our APAC business, to ensure continued access to our medicines for patients, securing the future for as many of our employees as possible and ensuring sustainability. This transformation will enhance our efficiency and agility, empowering our team to make a great impact on patient lives and make people smile," Abdul Mullick, Kyowa Kirin Chief International Business Officer.